Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Claritin D (Loratadine and Pseudoephedrine) - Uses, Dose, Brands

Claritin D contains Loratadine and Pseudoephedrine. Loratadine is an antiallergic drug (antihistamine). Pseudoephedrine is a decongestant and sympathomimetic.

Loratadine and Pseudoephedrine (Claritin D) Uses:

Cold and allergic symptoms:
- It is used to temporarily relieve sinusitis, hay fever, allergic rhinitis, runny nose, itching, throat irritation, watery eyes, and other allergy symptoms of the upper respiratory tract. It is also indicated for the temporary treatment of nasal and sinus congestion.

Loratadine and Pseudoephedrine (Claritin D) Dose in Adults:

Loratadine and Pseudoephedrine (Claritin D) Dose in the treatment of Cold and allergic symptoms:

Loratadine 5 mg/ pseudoephedrine 120 mg per tablet:
- Two tablets per day, taken every 12 hours.
- Two pills per day is the maximum dosage.
Loratadine 10 mg/ pseudoephedrine 240 mg per tablet:
- once day, one tablet
- One tablet per day is the maximum dose.

Loratadine and Pseudoephedrine (Claritin D) Dose in Children:

Loratadine and Pseudoephedrine (Claritin D) Dose in the treatment of Seasonal allergic rhinitis and as a nasal decongestant:

Children ≥12 years and Adolescents:
- 12-hour formulation (loratadine 5 mg and pseudoephedrine 120 mg):
  - One tablet twice daily, administered orally every 12 hours.
- 24-hour formulation (loratadine 10 mg and pseudoephedrine 240 mg):
  - One tablet once a day.

Dose in Pregnancy & lactation

See individual agents (Loratadine and Pseudoephedrine).
Both the drugs are labeled as Category B during pregnancy.

Dose in Kidney Disease:

It should be used with caution in patients with kidney disease.
However, Dosage adjustments have not been provided in the manufacturer's labeling.

Dose in Liver disease:

It should be used with caution in patients with liver disease.
However, Dosage adjustments have not been provided in the manufacturer's labeling.

Side effects of Claritin D:

See side effects of loratadine. See side effects of Pseudoephedrine.

Contraindications to Loratadine and Pseudoephedrine (Claritin D):

Allergy to pseudoephedrine, loratadine or any other component of the formulation
MAOI therapy can be completed within the first 14 days.
Patients suffering from severe hypertension or coronary disease

Warnings and precautions

Cardiovascular disease
- Patients with hypertension, angina, ischemic heart disease, or other cardiovascular conditions should not use it.
Diabetes:
- Patients with diabetes mellitus should not take the drug.
Hepatic impairment
- Patients suffering from liver disease should be cautious when taking the drug.
Glaucoma/increased intraocular pressure
- Patients with glaucoma and those with elevated intraocular pressure should use it with caution.
Prostatic hyperplasia/urinary block:
- Patients suffering from genitourinary obstruction or prostatic hyperplasia must be cautious when taking the drug.
Renal impairment
- Patients with impaired kidney function should not use it.
Thyroid dysfunction:
- Hyperthyroid patients should be cautious about taking the drug.

Loratadine and pseudoephedrine: Drug Interaction

Risk Factor C (Monitor therapy)
Acetylcholinesterase Inhibitors	May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.
Alcohol (Ethyl)	Alcohol's CNS depressing effect may be amplified by CNS depressants (Ethyl).
Alizapride	CNS depressants may have an enhanced CNS depressant impact.
Alkalinizing Agents	May raise the serum level of beta- and alpha-agonists (IndirectActing).
Alpha1-Blockers	May lessen the vasoconstriction caused by alpha/beta agonists. The vasodilation caused by Alpha1-Blocker may also be resisted by Alpha-/Beta-Agonists.
Amantadine	May strengthen an anticholinergic agent's anticholinergic action.
Amezinium	Antihistamines may intensify Amezinium's stimulant effects.
Amphetamines	May lessen antihistamines' sedative effects.
Anticholinergic Agents	Other anticholinergic agents' negative or hazardous effects might be amplified.
AtoMOXetine	Could make sympathomimetics' hypertensive effects stronger. The tachycardic impact of sympathomimetics may be increased by atoMOXetine.
Betahistine	Antihistamines may diminish the therapeutic effect of Betahistine.
Botulinum Toxin-Containing Products	May enhance the anticholinergic effect of Anticholinergic Agents.
Brexanolone	CNS Depressants may enhance the CNS depressant effect of Brexanolone.
Brimonidine (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Bromopride	May enhance the CNS depressant effect of CNS Depressants.
Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Cannabis	May enhance the CNS depressant effect of CNS Depressants.
Carbonic Anhydrase Inhibitors	May raise the serum level of beta- and alpha-agonists (Indirect-Acting).
Chloral Betaine	May worsen anticholinergic agents' harmful or hazardous effects.
Chloroprocaine	Alpha-/Beta-Agonists' hypertensive effects might be amplified.
Chlorphenesin Carbamate	May enhance the adverse/toxic effect of CNS Depressants.
CNS Depressants	May enhance the adverse/toxic effect of other CNS Depressants.
Dimethindene (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Doxofylline	Sympathomimetics may enhance the adverse/toxic effect of Doxofylline.
Doxylamine	May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended.
Dronabinol	May enhance the CNS depressant effect of CNS Depressants.
Erdafitinib	May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.
Esketamine	CNS depressants may have an enhanced CNS depressant impact.
Gastrointestinal Agents (Prokinetic)	Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).
Glucagon	Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.
Guanethidine	May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.
HydrOXYzine	May enhance the CNS depressant effect of CNS Depressants.
Itopride	Anticholinergic Agents may diminish the therapeutic effect of Itopride.
Kava Kava	May enhance the adverse/toxic effect of CNS Depressants.
Lofexidine	May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Lumacaftor	May lower the level of P-glycoprotein/ABCB1 Substrates in the serum. The serum concentration of P-glycoprotein/ABCB1 Substrates may rise when using lumacaftor.
Magnesium Sulfate	CNS depressants may have an enhanced CNS depressant impact.
MetyroSINE	The sedative effects of metyroSINE may be strengthened by CNS depressants.
Mianserin	May strengthen an anticholinergic agent's anticholinergic action.
Minocycline (Systemic)	CNS depressants may have an enhanced CNS depressant impact.
Mirabegron	Anticholinergic drugs may make Mirabegron's harmful or hazardous effects worse.
Nabilone	CNS depressants may have an enhanced CNS depressant impact.
Nitroglycerin	Nitroglycerin absorption may be decreased by anticholinergic agents. Anticholinergic medications specifically have the potential to impede or prevent the absorption of nitroglycerin by reducing the breakdown of sublingual nitroglycerin pills.
P-glycoprotein/ABCB1 Inducers	May lower the level of Pglycoprotein/ABCB1 Substrates in the serum. P-glycoprotein inducers may also further restrict the distribution of p-glycoprotein substrates to particular cells, tissues, and organs that have high levels of p-glycoprotein (e.g., brain, T-lymphocytes, testes, etc.).
P-glycoprotein/ABCB1 Inhibitors	Pglycoprotein/ABCB1 Substrates serum levels can rise. Additionally, p-glycoprotein inhibitors may improve the distribution of pglycoprotein substrates to particular cells, tissues, and organs where high levels of p-glycoprotein are present (e.g., brain, T-lymphocytes, testes, etc.).
Piribedil	Piribedil's CNS depressing effects may be enhanced by other CNS depressants.
Pramipexole	CNS Depressants may enhance the sedative effect of Pramipexole.
Ramosetron	Anticholinergic Agents may enhance the constipating effect of Ramosetron.
Ranolazine	May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.
ROPINIRole	CNS Depressants may enhance the sedative effect of ROPINIRole.
Rotigotine	CNS Depressants may enhance the sedative effect of Rotigotine.
Rufinamide	May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
Selective Serotonin Reuptake Inhibitors	CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Solriamfetol	Sympathomimetics may intensify Solriamfetol's hypertensive effects.
Spironolactone	May lessen the vasoconstrictor effects of alpha/beta antagonists
Sympathomimetics	Could intensify the hazardous or harmful effects of other sympathomimetics.
Tedizolid	Could make sympathomimetics' hypertensive effects stronger. The tachycardic impact of sympathomimetics may be increased by tedizolid.
Tetrahydrocannabinol	May enhance the CNS depressant effect of CNS Depressants.
Tetrahydrocannabinol and Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Thiazide and Thiazide-Like Diuretics	Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics.
Topiramate	Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.
Trimeprazine	May enhance the CNS depressant effect of CNS Depressants.
Urinary Acidifying Agents	May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).
Risk Factor D (Consider therapy modification)
Amiodarone	May raise the level of loratadine in the serum. Management: When possible, look into alternatives to loratadine due to reported QT interval prolongation and Torsades de Pointes with this combination.
Benzylpenicilloyl Polylysine	Antihistamines may reduce Benzylpenicilloyl Polylysine's ability to diagnose. Management: Delay testing until systemic antihistaminic effects have subsided and discontinue systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing. To determine whether permanent antihistaminic effects exist, a histamine skin test may be utilised.
Benzylpenicilloyl Polylysine	Alpha-/Beta-Agonists may lessen the Benzylpenicilloyl Polylysine's ability to diagnose. Management: To evaluate a patient's capacity to mount a wheal and flare response, consider using a histamine skin test as a positive control.
Blonanserin	CNS Depressants may enhance the CNS depressant effect of Blonanserin.
Buprenorphine	CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.
Chlormethiazole	May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.
Cocaine (Topical)	Could make sympathomimetics' hypertensive effects stronger. Management: Whenever possible, look at alternatives to using this combo. When used concurrently, keep a close eye out for noticeably elevated blood pressure or heart rate as well as any signs of myocardial ischemia.
Droperidol	CNS depressants may have an enhanced CNS depressant impact. Consider lowering the dosage of droperidol or other CNS drugs (such as opioids or barbiturates) when they are used concurrently. In separate drug interaction monographs, exceptions to this monograph are covered in more detail.
Flunitrazepam	CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.
Hyaluronidase	Antihistamines may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.
HYDROcodone	CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Lemborexant	May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.
Linezolid	May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available.
Methotrimeprazine	CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.
Opioid Agonists	CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
OxyCODONE	CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Perampanel	May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.
Pramlintide	May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.
Secretin	Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.
Serotonin/Norepinephrine Reuptake Inhibitors	Alpha-/Beta-Agonists' tachycardic impact may be boosted. The vasopressor impact of alpha/beta agonists may be enhanced by serotonin/norepinephrine reuptake inhibitors.
Sodium Oxybate	May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.
Suvorexant	CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.
Tapentadol	May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Tricyclic Antidepressants	May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.
Zolpidem	CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.
Risk Factor X (Avoid combination)
Aclidinium	May enhance the anticholinergic effect of Anticholinergic Agents.
Azelastine (Nasal)	CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).
Bromperidol	May enhance the CNS depressant effect of CNS Depressants.
Cimetropium	Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium.
Eluxadoline	Eluxadoline's constipating effects may be enhanced by anticholinergic drugs.
Ergot Derivatives	Alpha-/Beta-Agonists' hypertensive effects might be amplified. Alpha-/Beta-Agonists' vasoconstrictive effects may be strengthened by ergot derivatives. Exceptions: Mesylates of ergoloid; nicergoline.
Glycopyrrolate (Oral Inhalation)	Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation).
Glycopyrronium (Topical)	May enhance the anticholinergic effect of Anticholinergic Agents.
Iobenguane Radiopharmaceutical Products	Alpha-/Beta-Agonists (Indirect-Acting) may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.
Ipratropium (Oral Inhalation)	May enhance the anticholinergic effect of Anticholinergic Agents.
Lasmiditan	May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.
Levosulpiride	Levosulpiride's therapeutic impact may be diminished by anticholinergic medications.
Monoamine Oxidase Inhibitors	Might make alpha-/beta-agonists' hypertensive effects more pronounced (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid.
Orphenadrine	CNS Depressants may enhance the CNS depressant effect of Orphenadrine.
Oxatomide	May enhance the anticholinergic effect of Anticholinergic Agents.
Oxomemazine	May enhance the CNS depressant effect of CNS Depressants.
Paraldehyde	CNS Depressants may enhance the CNS depressant effect of Paraldehyde.
Pitolisant	Antihistamines may diminish the therapeutic effect of Pitolisant.
Potassium Chloride	Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.
Potassium Citrate	Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.
Revefenacin	Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin.
Thalidomide	CNS Depressants may enhance the CNS depressant effect of Thalidomide.
Tiotropium	Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.
Umeclidinium	May enhance the anticholinergic effect of Anticholinergic Agents.

Monitoring parameters:

None mentioned.

How to administer Loratadine and Pseudoephedrine (Claritin D)?

It is administered orally. The tablets should not be divided, chewed, crushed, or dissolved.

Mechanism of action of Loratadine and Pseudoephedrine (Claritin D):

Claritin D includes Loratadine (and Pseudoephedrine)

Loratadine MOA and Pharmacology

loratadine has specific peripheral histamine H-1 receptor antagonistic effects.

Notice:Children aged 2-12 years have a similar pharmacokinetic profile to adults.

The onset of action:

1-3 hours.

Peak effect:

8-12 hours.

Duration of action:

More than 24 hours.

Absorption:

It is rapidly absorbed;
Food increases total bioavailability (AUC) by 40% to 48%.

Distribution:

A tricyclic antihistamine with a long half-life,
no appreciable entry into CNS.

Protein binding:

97% to 99% (loratadine),
73% to 76% (metabolite).

Metabolism:

It is extensively metabolized in the liver via CYP2D6 and 3A4 to an active metabolite (des-carboethoxy loratadine).

Half-life elimination:

8.4 hours (range: 3 to 20 hours) (loratadine),
28 hours (range: 8.8 to 92 hours) (metabolite).
hepatic impairment:
- 24 hours (loratadine),
- 37 hours (metabolite).

Time to peak serum concentration:

Loratadine: 1.3 hours,
2.3 hours (metabolite).

Excretion:

Urine (40%) and feces (40%) as metabolites.

Pseudoephedrine MOA and Pharmacology:

It binds predominantly to H-1 receptors in the peripheral nervous system.

The onset of action:

Decongestant: Oral: 30 minutes

Peak effect:

Decongestant: Oral: ~1-2 hours

Duration:

Immediate release tablet: 3-8 hours

Absorption:

Rapid

Metabolism:

It is metabolized via n-demethylation to convert into its active form nor-pseudoephedrine
Hepatic (<1%).

Half-life elimination:

Variable according to urine pH and flow rate;
- alkaline urine decreases renal elimination of pseudoephedrine.
Children: ~3 hours (urine pH ~6.5)
Adults: 9-16 hours (pH 8); 3-6 hours (pH 5)

Time to peak:

Children (immediate-release) ~2 hours
Adults (immediate-release): 1-3 hours (dose-dependent)

Excretion:

Urine (43% to 96% as unchanged drug, 1% to 6% as active norpseudoephedrine);
The excretion depends on urine pH and flow rate;
- alkaline urine decreases renal elimination of pseudoephedrine.

International Brand Names of Loratadine and pseudoephedrine:

Alavert Allergy and Sinus
Allergy Relief-D
Claritin-D 12 Hour Allergy & Congestion
Claritin-D 24 Hour Allergy & Congestion
Loratadine-D 12 Hour
Loratadine-D 24 Hour
Chlor-Tripolon ND
Claritin Extra
Claritin Liberator
Airet
Aldisa-SR
Alergicol LP
Allerpid
Bonalerg - D
Carinox
Clariflu
Clarifriol
Clarinase
Clarinase 24 Hour Extended Release
Clarinase 24 Hour Relief
Clarinase Repetabs
ClaritineD
Clarityn-D 12 hour Repetabs
Clarityn-D 24 hour Repetabs
Clarityne
Clarityne D Repetabs
Clarityne Plus
Clarityne-D
Coderin ER
Cronase
De-Cold
Defonase
Dimegan D
Gralddep
Larotin D
Lertamine D
Lertamine Repetabs
Lodin Plus
Lorfast-D
Lorimox
Lorinase
Minlife-P
Narine
Rhilor D
Rhinos SR
Sensibit
Sudo PLUS
Theraflu
Tricel-D
Zoratadine-P

Loratadine and pseudoephedrine Brand Names in Pakistan:

Loratadine and pseudoephedrine Tablets 5 mg
Rhilor D	Pharmatec Pakistan (Pvt) Ltd.

Loratadine and pseudoephedrine Tablets SR 5 mg
Clarinase Repetabs	ICI Pakistan Ltd.

Claritin D (Loratadine and Pseudoephedrine) - Uses, Dose, Brands

Loratadine and Pseudoephedrine (Claritin D) Uses:

Cold and allergic symptoms:

Loratadine and Pseudoephedrine (Claritin D) Dose in Adults:

Loratadine and Pseudoephedrine (Claritin D) Dose in the treatment of Cold and allergic symptoms:

Loratadine 5 mg/ pseudoephedrine 120 mg per tablet:

Loratadine 10 mg/ pseudoephedrine 240 mg per tablet:

Loratadine and Pseudoephedrine (Claritin D) Dose in Children:

Loratadine and Pseudoephedrine (Claritin D) Dose in the treatment of Seasonal allergic rhinitis and as a nasal decongestant:

Children ≥12 years and Adolescents:

Dose in Pregnancy & lactation

Dose in Kidney Disease:

Dose in Liver disease:

Side effects of Claritin D:

Contraindications to Loratadine and Pseudoephedrine (Claritin D):

Warnings and precautions

Cardiovascular disease

Diabetes:

Hepatic impairment

Glaucoma/increased intraocular pressure

Prostatic hyperplasia/urinary block:

Renal impairment

Thyroid dysfunction:

Monitoring parameters:

How to administer Loratadine and Pseudoephedrine (Claritin D)?

Mechanism of action of Loratadine and Pseudoephedrine (Claritin D):

Loratadine MOA and Pharmacology

Pseudoephedrine MOA and Pharmacology:

International Brand Names of Loratadine and pseudoephedrine:

Loratadine and pseudoephedrine Brand Names in Pakistan:

Loratadine and pseudoephedrine Tablets 5 mg

Loratadine and pseudoephedrine Tablets SR 5 mg

Recent Posts

Related Posts